Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 13/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.80 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.46 |
| ▸ | CDK9 | P50750 | 5/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12349866 | 0.89 | HCAR3 (0.64) | HCAR3HPGDHCAR2CCNT1CDK9 | |
| SCHEMBL839123 | 0.89 | HCAR3 (1.00) | HCAR3HPGDHCAR2 | |
| SCHEMBL6186432 | 0.82 | HCAR3 (0.56) | HCAR3HPGDHCAR2 | |
| SCHEMBL12171899 | 0.81 | HCAR3 (0.59) | HCAR3HPGDHCAR2CCNT1CDK9 | |
| SCHEMBL2741825 | 0.81 | HCAR3 (0.54) | HCAR3HPGDHCAR2CCNT1CDK9 | |
| SCHEMBL1256199 | 0.80 | HCAR3 (0.76) | HCAR3HPGDHCAR2 | |
| SCHEMBL6183444 | 0.79 | HCAR3 (0.52) | HCAR3HPGDHCAR2CCNT1CDK9 | |
| SCHEMBL12171889 | 0.79 | HPGD (0.55) | HCAR3HPGDHCAR2CCNT1CDK9 | |
| SCHEMBL2852713 | 0.78 | HSD17B10 (0.56) | HCAR3HPGDHCAR2 | |
| SCHEMBL6183836 | 0.78 | HCAR3 (0.51) | HCAR3HPGDHCAR2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1247810-B1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6664395-B2 | Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1247810-A1 | Novel benzotriazoles anti-inflammatory compounds | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | MAPK1, JAK1, RUNX1 | HCAR3 495/4885HPGD 1292/4885HCAR2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.